Drug Profile
WT 2725
Alternative Names: WT-2725Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Osaka University School of Medicine
- Developer Sumitomo Pharma; Sumitomo Pharma America
- Class Antineoplastics; Cancer vaccines; Peptide vaccines; Peptides
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Haematological malignancies; Solid tumours
Most Recent Events
- 01 Apr 2022 Sumitomo Dainippon Pharma is now called Sumitomo Pharma
- 28 Feb 2020 No recent reports of development identified for phase-I development in Haematological-malignancies(Late-stage disease) in USA (Parenteral, Injection)
- 28 Feb 2020 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in USA (Parenteral, Injection)